Actualités et Activités de Encoded Therapeutics
Dirigeants
Voir l'organigramme avec ses 23 principaux dirigeants
Biographies les plus recherchées chez Encoded Therapeutics
- Kartik Ramamoorthi, Chief Executive Officer and Director
- Karan Takhar, Director
- Sean Nolan, Chairman of the Board
Changements de dirigeants chez Encoded Therapeutics
- Jack Kane, Vice President, Engineering, a quitté l'entreprise (publié le 22 juin 2026).
- Joseph Sullivan, a rejoint l'entreprise comme Vice President of Clinical Development (publié le 18 décembre 2025).
Créer une alerte
pour suivre les mouvements de dirigeants chez Encoded Therapeutics.
Biotechnologie
Encoded Therapeutics a 2 429 concurrents dont Lonza (Suisse), Vertex Pharmaceuticals (Etats—Unis) et Eurofins (Luxembourg).
Actualités en fusion/acquisition en Biotechnologie.
- Eli Lilly has announced the acquisition of AtaiBeckley (publié le 17 juillet 2026).
- GSK a acquis Nuvalent (publié le 17 juillet 2026).
- Clearside Biomedical has gone out of its bankruptcy protection (publié le 15 juillet 2026).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Encoded Therapeutics
- Encoded Demonstrates Therapeutic Potential of a Vectorized miRNA-based Approach for Angelman Syndrome at the FAST Annual Global Science Summit
- Encoded Therapeutics Presents Preclinical Data Across its Gene Therapy Portfolio at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
- Encoded Therapeutics Provides Pipeline Updates From Its Vector Engineering Platform Ahead of Four Preclinical Presentations at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
- Encoded Therapeutics Announces UK CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101
- Encoded Therapeutics Announces US IND Clearance and Australian CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101
- Our platform to discover and validate regulatory elements to drive targeted transgene expression for use in gene therapies
- Encoded Therapeutics Addresses Common Source of Gene Therapy Toxicity While Achieving Precise Brain Expression in Non-Human Primates, Presented at the American Society of Gene and Cell Therapy 26th Annual Meeting
- Building Customized Gene Expression Profiles
- Gene therapy targets interneurons to tackle Dravet syndrome | Spectrum | Autism Research News
- Enabling Precise Control of Expression for Potentially Improved Gene Therapy Safety and Efficacy Profiles
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Encoded Therapeutics
- Encoded Therapeutics sur Wikipédia, Google News & Yahoo Finance en 1-click
- Encoded Therapeutics sur LinkedIn, X (Twitter) & YouTube en 1-click
